A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Skingenix, Inc.
ClinicalTrials.gov Identifier:
NCT01070433
First received: February 16, 2010
Last updated: January 6, 2014
Last verified: January 2014
  Purpose

The objective of this study is to evaluate the safety and efficacy of MEBO in the treatment of subjects with diabetic foot ulcers (DFUs).


Condition Intervention Phase
Diabetic Foot Ulcers
Drug: MEBO Wound Ointment (MEBO)
Procedure: Standard of Care
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Controlled, Multi-Center Study of the Safety and Efficacy of Topically Applied MEBO Wound Ointment Compared to Standard of Care in Subjects With Diabetic Foot Ulcers

Resource links provided by NLM:


Further study details as provided by Skingenix, Inc.:

Primary Outcome Measures:
  • The incidence of complete healing of the target ulcer. [ Time Frame: 8 week treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time required to achieve complete healing (days). [ Time Frame: 8 week treatment period ] [ Designated as safety issue: No ]
  • Absolute and percentage change in ulcer surface area from baseline to endpoint. [ Time Frame: 8 week treatment period ] [ Designated as safety issue: No ]

Enrollment: 75
Study Start Date: September 2012
Study Completion Date: December 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MEBO Wound Ointment (MEBO)
Topical application twice a day
Drug: MEBO Wound Ointment (MEBO)
Topical application twice a day
Active Comparator: Standard of Care
Topical application twice a day
Procedure: Standard of Care

Detailed Description:

This is a phase II, randomized, controlled, multi-center study designed to assess the safety and efficacy of MEBO in the treatment of subjects with DFUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ≥18 years of age
  • Able and willing to provide informed consent
  • Able and willing to comply with protocol visits and procedures
  • Target ulcer duration of ≥4 weeks

Exclusion Criteria:

  • Ulcer of a non-diabetic pathophysiology
  • Known or suspected allergies to any of the components of MEBO
  • Malignancy on target ulcer foot
  • Non-compliance in the screening or run-in period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01070433

Locations
United States, Arizona
HOPE Research Institute
Phoenix, Arizona, United States, 85032
United States, California
Center for Clinical Research, Inc.
Castro Valley, California, United States, 94546
ILD Consulting, Inc.
Encinitas, California, United States, 92024
Sacramento Foot and Ankle Center
Fair Oaks, California, United States, 95628
Valley Vascular Surgery Associates
Fresno, California, United States, 93720
Foot and Ankle Clinic
Los Angeles, California, United States, 90010
United States, Nevada
Advanced Foot and Ankle Center
Las Vegas, Nevada, United States, 89119
United States, Texas
Complete Family Foot Care
McAllen, Texas, United States, 78501
Endeavor Clinical Trials, San Antonio Podiatry Associates
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Skingenix, Inc.
Investigators
Study Chair: Robert S Kirsner, MD, PhD University of Miami
  More Information

No publications provided

Responsible Party: Skingenix, Inc.
ClinicalTrials.gov Identifier: NCT01070433     History of Changes
Other Study ID Numbers: MEBO-DFU-PII-001 v. 4.0
Study First Received: February 16, 2010
Last Updated: January 6, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Skingenix, Inc.:
Diabetic Foot Ulcers (DFUs)

Additional relevant MeSH terms:
Ulcer
Foot Ulcer
Diabetic Foot
Pathologic Processes
Foot Diseases
Skin Diseases
Leg Ulcer
Skin Ulcer
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies

ClinicalTrials.gov processed this record on September 14, 2014